Overview
- The Autorité de la concurrence found Doctolib dominant since 2017 in online medical appointment booking and teleconsultation, citing an estimated 70% to 90% market share.
- Regulators faulted exclusivity clauses for practitioners and the tying of access to Doctolib's teleconsultation to its broader software suite.
- The 2018 purchase of rival Mondocteur was deemed to have removed a key competitor, which the authority presented as a first-time inclusion of an acquisition in an abuse-of-dominance ruling.
- The case stems from a complaint filed roughly eight years ago by competitor Cegedim and followed multi-year investigations and on-site searches.
- Doctolib argues it is not dominant, says the relevant markets cannot be separated from its integrated product, notes it equips about 30% of French caregivers, and indicates it will cover the sanction from recent profits.